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The majority of patients with advanced cancer are recognised by impaired immune competence influenced by several factors,
including the type and stage of the tumour and the presence of cachexia. Recently, a specific nutritional combination containing fish
oil, specific oligosaccharide mixture, high protein content and leucine has been developed aimed to support the immune system of
cancer patients in order to reduce the frequency and severity of (infectious) complications. In a recently modified animal model
cachexia is induced by inoculation of C26 tumour cells in mice. In a pre-cachectic state, no effect was observed on contact
hypersensitivity, a validated in vivo method to measure Th1-mediated immune function, after adding the individual nutritional
ingredients to the diet of tumour-bearing mice. However, the complete mixture resulted in significantly improved Th1 immunity.
Moreover, in a cachectic state, the complete mixture reduced plasma levels of pro-inflammatory cytokines and beneficially affected ex
vivo immune function. Accordingly, the combination of the nutritional ingredients is required to obtain a synergistic effect, leading to a
reduced inflammatory state and improved immune competence. From this, it can be concluded that the specific nutritional
combination has potential as immune-supporting nutritional intervention to reduce the risk of (infectious) complications in cancer
patients.
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Cancer patients are recognised to be hampered by serious immune
failures, especially patients with tumours of the head, neck, lung,
oesophagus, cervix and breast (Pak et al, 1995; Mafune and
Tanaka, 2000; Hadden, 2003). Several underlying mechanisms of
immune dysfunction have been described to affect innate and
adaptive immunity, leading to a poorer clinical outcome (Young,
1994; Young et al, 1996; Heimdal et al, 1999; Herber et al, 2007).
The degree of immune dysfunction depends on the type and stage
of the tumour, performance status, age, anti-tumour therapies,
malnutrition and the presence of cachexia (Pak et al, 1995; Young
et al, 2001; Argiles, 2005; Evans et al, 2006; Whiteside, 2006).
Cancer cachexia occurs in the majority of patients with
advanced cancer. It is inversely correlated with the survival time
of the patient and it always implies a poor prognosis (McNamara
et al, 1992; Ross and Fearon, 2002; Zhou et al, 2003; Van Cutsem
and Arends, 2005; Argiles et al, 2007). Cachexia is characterised by
progressive, involuntary weight loss, wasting, anorexia, asthenia,
fatigue and impaired immune function (Toomey et al, 1995; Puccio
and Nathanson, 1997; Finley, 2000; Argiles, 2005; Van Cutsem and
Arends, 2005). It has been estimated to account for 10–30% of
cancer deaths, but might also contribute to deaths by other causes
such as opportunistic infections (Warren, 1932; Inagaki et al, 1974;
Barton, 2001).
Several mediators that are either tumour- or host-derived, such
as pro-inflammatory cytokines, eicosanoids and hormones, have
been implicated in the pathogenesis of cancer cachexia (Tisdale,
1997; Ross and Fearon, 2002; Argiles, 2005; Van Cutsem and
Arends, 2005). The pro-inflammatory cytokines interleukin (IL)-
1b, IL-6, tumour necrosis factor (TNF)-a and interferon (IFN)-g
(also called pro-cachectic cytokines) are thought to be responsible
for the metabolic changes associated with cancer cachexia through
different mechanisms (Toomey et al, 1995; Argiles et al, 2003; Van
Cutsem and Arends, 2005; Morley et al, 2006). These cytokines
each play a specific role, but it has become clear that overlapping
biological activities and synergistic interactions between them lead
to a progressive cachectic state (McNamara et al, 1992; Toomey
et al, 1995; Argiles, 2005). An excessive amount of these cytokines,
together with the major eicosanoid prostaglandin E2 (PGE2), lead
to impaired immune responses that have been characterised in
vivo by a progressive decrease in delayed-type hypersensitivity to
recall antigens and to dinitrochlorobenzene (Stein et al, 1976;
Haffejee and Angorn, 1979; Singh et al, 1979). Accordingly, a
reduced ex vivo proliferation response of T lymphocytes to
mitogens has been reported (Anderson et al, 1981; Wustrow and
Issing, 1993; Hadden, 2003). Functionally, this leads to a higher
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ssusceptibility to infections in cachectic patients (Argiles, 2005;
Ben-Baruch, 2006).
A good nutritional status is of major importance to maintain
immune function in (pre-)cachectic cancer patients (Argiles,
2005). Nutritional interventions should therefore be recognised
as an integral part of cancer therapy to improve clinical outcomes
and quality of life (van Bokhorst-de van der Schueren, 2005). Early
provision of nutritional support can stop or even reverse the
decline in the nutritional status, and thus prevent the development
of malnutrition and slowdown the progression of cachexia
(Argiles, 2005; Correia et al, 2007). This is expected to lead to a
better response to therapy and fewer treatment-related complica-
tions. Recently, a specific nutritional combination (SNC) has been
developed to support the immune system of catabolic cancer
patients before the onset of weight loss or already suffering from
cachexia in order to reduce the frequency and severity of
(infectious) complications. The SNC is based on four active
nutritional ingredients, namely fish oil (FO), specific oligosaccha-
ride mixture (SOM), high protein content and leucine (high
protein/leucine), in which FO and SOM have been selected for their
potential effects on the immune system.
Fish oil is a generally used ingredient in immune-modulating
nutritional interventions, containing the conditionally essential
long-chain n-3 polyunsaturated fatty acids (PUFAs) eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA). These long-
chain n-3 PUFAs possess a wide range of anti-inflammatory
activities, including a decreased production of the inflammatory
mediator PGE2 and the pro-inflammatory cytokines TNF-a, IL-1b,
IL-6 and IL-8 (Calder, 2006). In tumour-bearing rats, n-3 PUFAs
prevented the decrease in body weight (BW) because of cachexia,
and as a consequence, survival was increased significantly (Pizato
et al, 2006). Clinical evidence of immune-modulating activities of
long-chain n-3 PUFAs exists (van Bokhorst-de van der Schueren,
2005), however, generally without affecting systemic immune
biomarkers (Sijben and Calder, 2007). The optimal dose, formula-
tion, relative contributions of EPA and DHA in fish oil and the
target population remain yet to be defined (Fearon et al, 2006;
Sijben and Calder, 2007). The use of non-digestible carbohydrates,
especially of prebiotic oligosaccharides, is based on the immune-
modulating activities observed in several animal experiments and
clinical trials (Vos et al, 2007). In an influenza vaccination model
in healthy C57BL/6 mice, a specific mixture of oligosaccharides
stimulated the vaccine-specific delayed-type hypersensitivity
response as a marker for T-helper 1 (Th1) immunity (Vos et al,
2006). Enhancing systemic Th1-dependent adaptive immune
responses would lead in theory to better immune responses
against infections that have been confirmed by applications in
clinical trials (Bruzzese et al, 2006; Arslanoglu et al, 2007).
The addition of high protein and the branched chain amino acid
leucine to the product focuses on alterations in protein metabolism
in cancer patients and might in combination with fish oil have a
positive effect on skeletal muscle function, lean body mass and
daily activity (unpublished data).
In this study, the effects of the individual nutritional ingredients,
FO, SOM and high protein/leucine, were investigated on inflam-
matory status, immune function and on different parameters for
cachexia. In addition, the effect of the complete mixture of these
nutritional ingredients was tested and compared with the
individual ingredients. The experiments were performed using a
recently modified and validated animal model for cancer cachexia,
based on the colon-26 tumour model, in which parameters of
immune function can be quantified. In this model, cachexia is
induced by the inoculation of murine colon adenocarcinoma (C26)
cells in syngenic CD2F1 mice (Tanaka et al, 1990), leading to
several cachectic features (Strassmann et al, 1992a; Tanaka et al,
1993; Soda et al, 1994). The model was extended by including
several immune parameters: contact hypersensitivity (CHS)
against oxazolone was measured in a pre-cachectic state as an
in vivo parameter for Th1-mediated immune function. In addition,
several ex vivo parameters were measured at a later time point,
when the animals were in a cachectic state. These pre-clinical
experiments were performed to evaluate the potential benefits of
specific nutritional interventions for immune function, which
might lead to new applications for cancer patients.
MATERIALS AND METHODS
Animals and diets
Six to seven-week-old syngenic male CD2F1 mice (BALB/c DBA/2)
were obtained from Harlan Nederland (Horst, The Netherlands). All
experimental procedures were approved by the Animal Experimental
Committee and complied with the principles of laboratory animal
care. Animals were housed individually in a climate-controlled animal
care facility with a constant room temperature and humidity. All
animals had free access to food and drinking water. Upon arrival,
animals were acclimatised for 1 week and subsequently randomised
on the basis of BW. The experiments were divided into: experiments
A, designed to test the effect of the individual ingredients, and
experiments B, designed to test the effect of the complete mixture of
ingredients that resembles the composition of the new generation
FortiCare (Nutricia Advanced Medical Nutrition, Zoetermeer, The
Netherlands). In both experiments A and B, mice were divided into a
control group (C) receiving control diet, a tumour-bearing control
group (TB) receiving control diet and tumour-bearing experimental
groups (TB-nutritional ingredient). Data shown are derived from the
combination of several experimental runs with identical animal
characteristics and experimental procedures (unless stated otherwise).
The tumour-bearing experimental group in the experiments A
received a diet based on AIN93-M (Research Diet Services, Wijk bij
Duurstede, The Netherlands) with fish oil (TB-FO), SOM (TB-
SOM) or high protein enriched with leucine (TB-HPrleu) supplied
as pellets, and in the experiments B, a diet with the combination of
fish oil, SOM and high protein/leucine (TB-SNC). The latter diet
differed in the macronutrient composition from AIN93-M to
achieve a more humanised diet supplied as dough for product
technical reasons.
The control diet in the experiments A contained per kg food:
126g protein (100% casein), 727g carbohydrates and 40g fat
(100% soy oil). The experimental diets in the experiments A were
adapted by adding 22.1g fish oil (providing 6.9g EPA and 3.1g
DHA) per kg food (TB-FO), 18g short-chain galacto-oligosaccha-
rides (Vivinal GOS, Friesland Domo Foods, Zwolle, The Nether-
lands) and 2g short-chain fructo-oligosaccharides (Beneo p95,
Orafti, Wijchen, The Netherlands) per kg food (TB-SOM) or 151g
casein per kg and 16g leucine per kg food (TB-HPrleu).
The control diet in the experiments B contained more fat,
although the diet is isocaloric and isonitrogenous compared with
the control diet in experiments A, per kg food: 126g protein (100%
casein), 699g carbohydrates and 52.6g fat (100% corn oil). This
control diet did not show any effect on physiological cachexia
parameters and immune parameters in the used animal model
(data not shown). The experimental diet in experiments B
contained per kg food: 210g protein (189g intact protein of which
68% casein and 32% whey and 21g free leucine), 561g
carbohydrates, 52.5g fat (20.2g corn oil, 10.2g canola oil and
22.1g fish oil (providing 6.9g EPA and 3.1g DHA)), 18g short-
chain galacto-oligosaccharides and 2g short-chain fructo-oligo-
saccharides.
Experimental design
Murine colon-26 adenocarcinoma cells were used to induce
cachexia in mice (Tanaka et al, 1990; Strassmann et al, 1992a,b).
In short, on day 0, tumour cells (5 10
5 cells in 0.2ml) were
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sinoculated, under general anaesthesia (isoflurane/N2O/O2), sub-
cutaneously into the right inguinal flank of CD2F1 mice in the
tumour-bearing groups. Animals in the control group received a
sham injection with 0.2ml HBSS. Body weight, food intake and
tumour size (length and width) were measured three times a week.
To investigate effects on the immune system, CHS against
oxazolone was determined, as an in vivo model for cellular (Th1-
dependent) immunity. Briefly, on day 8, all animals were sensitised
with 150ml 3% oxazolone solution (4-ethoxymethylene-2-phenyl-
2-oxazolin-5-one; Sigma-Aldrich Chemie, Zwijndrecht, The Neth-
erlands; 300mg in 7.5ml 96% ethanol and 2.5ml acetone) applied
on their shaved breast and abdomen. Subsequently, at day 13, ear
thickness was measured under general anaesthesia and all animals
were hapten challenged with 25ml 0.8% oxazolone solution (32mg
in 3ml 96% ethanol and 1ml acetone) topical to the ear pinnae. At
day 14 after tumour inoculation (24h after the challenge), ear
swelling was measured under general anaesthesia to determine the
Th1 immune response.
At day 20, blood was collected by cardiac puncture and sampled
in heparin tubes. After killing, spleens were dissected, weighed and
stored in a cold culture medium (RPMI-1640 containing 25mM
HEPES and 2mML -glutamine; Life Technologies, Merelbeke,
Belgium; enriched with 100Uml
 1 penicillin/streptomycin) with
10% heat-inactivated foetal calf serum (FCS
hi) for immunological
analysis. Skeletal muscles (m. tibialis anterior (mTA), m. extensor
digitorum longus (mEDL), m. soleus (mS) and m. gastrocnemius
(mG)), tumour, epididymus fat and thymus were dissected,
weighted and frozen at  801C (skeletal muscles).
Immunological analysis
All ex vivo incubations of cells were performed at 371Ci na
humidified environment containing 5% CO2.
Whole blood assay Blood was added in 50ml/well to 100ml/well
culture medium in a 96-well plate and was subsequently incubated
with 50ml/well LPS (Fc 1mgml
 1, Escherichia coli, B55:O55; Sigma-
Aldrich Chemie) or culture medium (control) for 20h or with
ConA (Fc 40mgml
 1, concanavalin A from Canavalia ensiformis
type IV; Sigma-Aldrich Chemie) or culture medium (control) for
44h. Afterwards, supernatants were harvested and stored at  801C
until analysis. Plasma was obtained from the residual blood and
stored at  801C until analysis.
Splenocyte assay Splenocytes were isolated by pressing spleens
through cell strainers (40mm) into a 50ml tube. After erythrocyte
lysis, splenocytes were plated in 20ml per well (Fc 2 10
5 cells per
well) in a 96-well plate and 80ml per well culture medium with 10%
FCS
hi was added. Thereafter, cells were incubated with 100ml/well
LPS (Fc 1mgml
 1) or culture medium (control) for 20h for PGE2
and cytokine production or with 100ml/well ConA (Fc 3mgml
 1)
or culture medium (control) for 44h both for proliferation and
cytokine production. After 28h incubation, cells for proliferation
were labelled with 0.4mCi/well tritiated thymidine (
3H-thymidine;
Perkin Elmer, Zaventem, Belgium) and incubated for another 16h.
Subsequently, cells were harvested on Packard GF/C filter plates
(Perkin Elmer) and dried on air. Afterwards, 25ml scintillation
fluid (Packard Ultima Gold; Perkin Elmer) was added to the wells
and plates were counted in a scintillation counter (Wallac
MicroBeta radioactivity plate counter, Perkin Elmer). For PGE2
and cytokine production, plates were centrifuged and supernatants
were harvested and stored at  801C until analysis.
PGE2 and cytokine measurement Prostaglandin E2 was measured
using a commercial anti-PGE2 rabbit polyclonal antibody-based
direct enzyme immunoassay (Oxford Biomedical Research,
Oxford, MI, USA) according to the manufacturer’s protocol.
Cytokines in plasma were measured using a commercial mouse
cytokine 10-plex bead immunoassay (Biosource, Etten-Leur, The
Netherlands) according to the manufacturer’s protocol, and
cytokines in supernatants were measured using a commercial
mouse cytokine Th1/Th2 bead immunoassay or a commercial
mouse cytokine inflammatory bead immunoassay (both from
Biosource) according to the manufacturer’s protocol.
Flowcytometric analysis Splenocytes were added in 100ml to a 96-
well plate (Fc 1 10
6 cells/well), centrifuged and resuspended in
cold PBS with 1% FCS
hi and 0.1% sodium azide. Cells were
incubated with fluorescent-labelled antibodies for 30min on ice in
a total volume of 50ml. After washing, cells were analysed on an
Epics XL flowcytometer (Beckman Coulter, Mijdrecht, The Nether-
lands). The following monoclonal antibody combinations were
used: (1) GR-1-FITC (BD Pharmingen, Alphen aan den Rijn, The
Netherlands), F4/80-PE (Serotec Ltd., Oxford, UK) and 7-AAD
(Coulter Immunotech, Beckman Coulter); (2) CD3-FITC, CD4-PE-
CY5 (both from BD Pharmingen) and CD8-PE (Beckman Coulter);
(3) TCR-alpha-FITC, DX5-PE and CD19-PE-CY5 (all from Beckman
Coulter) and (4) unlabelled cells. Results were analysed using
Expo32 software (Beckman Coulter). The method to determine
positive cells using these antibodies was validated using isotype
control antibodies in earlier experiments. Dead 7-AAD
þ cells were
excluded in antibody combination (1). The forward- and side-
scatter profile from 7-AAD
  cells in combination (1) was used to
identify living cells and exclude dead cells in combinations (2), (3)
and (4).
Determination of phospholipid fatty acids in blood cells and
splenocytes Residual heparin blood and 1 10
7 splenocytes were
centrifuged and cell pellets were stored at  801C until analysis.
Phospholipids were separated from total cellular lipids using
Bond-Elut
s solid-phase extraction columns and the Vac-Elut SPS
24t system. Phospholipid extracts were converted into methyl
esters by using 10% BF3 in methanol at 1001C for 60min. After
hexane extraction, derivatised phospholipids were dissolved in iso-
octane, and the fatty acid composition was analysed by gas
chromatography using a capillary column (50m 0.25mm, CP-
SIL88-fame). Peaks were identified by commercial reference
standards.
Statistics All data were expressed as means±s.e.m. Statistical
analysis was performed using SPSS 12.0.1 (SPSS Benelux,
Gorinchem, The Netherlands). In the experiments A, different
batches of animals were used. For that reason, it was examined for
all parameters, by using ANOVA, if combination of the data was
allowed and if no interaction between the groups and experiments
existed. The effect of treatment was tested using a one-way
ANOVA, followed by LSD post hoc analysis when data were
normally distributed and showed equal variances. When equal
variances were not assumed, post hoc a Dunnett’s T3 test was
performed. A non-parametric Mann–Whitney U-test was per-
formed when data were not normally distributed. Differences were
considered significant at Po0.0125 (Table 1 and Figure 1) and
Po0.025 (Tables 2 and 3 and Figures 2 and 3) based on a/k,i n
which a¼0.05 and k is the number of comparisons.
RESULTS
Functional parameters measured in both experiments A
and B
Physiological cachexia and immune parameters At day 20 after
tumour inoculation, mice were killed and both cachexia and
immune parameters were measured. Data from the different
experiments with the individual nutritional ingredients
(experiments A) were combined and displayed in Table 1, and
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mixture of FO, SOM and high protein/leucine (experiment B) were
presented in Table 2. In experiments A, BW and carcass weight
(CW¼BW tumour weight (TW)) were significantly decreased
from 24.4g (both) in the control (C) group to 22.8 and 20.7g,
respectively, in the TB group, whereas in experiment B, a decrease
was observed from 25.7g (both) in the C group to 20.1 and 18.0g,
respectively, in the TB group. This reduction could be caused by
the significant weight loss of fat and skeletal muscles in the TB
group. Food intake has been controlled and was not affected in
both experiments A and B (data not shown).
The addition of one of the individual nutritional ingredients to
the diet did not result in any significant effect on BW or CW
compared with animals in the TB group. However, a diet
containing the complete mixture of FO, SOM and high protein/
leucine improved both BW and CW significantly from 20.1 and
18.0g, respectively, in the TB group to 21.9 and 20.3g, respectively,
in the TB-SNC group (Table 2), indicating a less cachectic state of
the mice. This was emphasised by a positive effect on other
cachectic features, such as a significant inhibition of weight loss of
epididymus fat and skeletal muscles, which was absent after
feeding a diet with the individual nutritional ingredients.
In both experiments A and B, thymus weight was significantly
decreased after tumour inoculation with 47.9 and 61.7%,
respectively, whereas spleen weight was more than twice as high
in the TB group as compared with the C group. After the addition
of FO or the complete mixture of FO, SOM and high protein/
leucine to the diet, a significant inhibition of thymus weight loss
was observed, whereas none of the individual nutritional
ingredients affected spleen weight (Table 2).
CHS A CHS test was performed at day 13/14 to determine in vivo
immune function prior to weight loss. Contact hypersensitivity
responses were significantly reduced in the TB group as compared
with the C group in experiments A (28.1%, Figure 1) and B (31.0%,
Figure 2a), indicating an impaired Th1 immune response in
tumour-bearing mice. After adding one of the individual nutri-
tional ingredients to the diet of tumour-bearing mice, no effect was
observed on this immune biomarker (Figure 1). However, after
administration of the complete mixture of FO, SOM and high
protein/leucine to the tumour-bearing mice (TB-SNC), immune
responsiveness was increased significantly by 20.7% compared
with the TB mice, indicating a better Th1-mediated immune
response (Figure 2a).
Additional immune parameters measured in experiment B
To obtain more information on immunocompetence and inflam-
matory status of tumour-bearing mice in a cachectic state and to
determine the effect of adding the complete mixture of FO, SOM
and high protein/leucine to the diet of these mice, several
additional immune parameters were measured after killing the
mice at day 20.
Flowcytometric analysis of splenocytes and determination of
phospholipid fatty acids Spleen weight was increased significantly
in tumour-bearing control animals because of an increase in the
number of spleen cells caused by an enormous expansion of
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Figure 1 Effects of oral administration of fish oil, specific oligosaccharide
mixture or high protein/leucine on contact hypersensitivity. Data represent
means (mm)±s.e.m. of the control (C) group (n¼20), tumour-bearing
control (TB) group (n¼20) and tumour-bearing groups after supple-
mentation with fish oil (TB-FO, n¼10), specific oligosaccharide mixture
(TB-SOM, n¼10) or high protein/leucine (TB-HPrleu, n¼10). *Signi-
ficantly different (Po0.0125) from the TB group.
Table 2 Effects of oral administration of the complete mixture of fish oil,
specific oligosaccharide mixture and high protein/leucine on physiological
cachexia parameters and immune parameters
Cachexia C TB TB-SNC
Body weight (g) 25.7±0.5* 20.1±0.4 21.9±0.5*
Tumour weight (g) 0.0±0.0 2.1±0.1 1.8±0.1 *
Carcass weight (g) 25.7±0.5* 18.0±0.3 20.3±0.5*
Epididymus fat (mg) 230.3±17.4* 40.9±10.9 88.2±10.9*
m. Tibialis anterior (mg) 44.7±1.0* 33.6±0.7 38.5±0.8*
m. EDL (mg) 8.9±0.2* 6.7±0.2 7.6±0.2*
m. Soleus (mg) 6.4±0.2* 4.8±0.1 5.4±0.2*
m. Gastrocnemius (mg) 132.1±2.4* 99.5±2.2 110.7±2.9*
Immune C TB TB-SNC
Thymus weight (mg) 36.8±1.8* 14.1±1.1 20.7±1.8*
Spleen weight (mg) 95.2±4.3* 210.5±14.3 209.8±9.3
Spleen cells (1 10
7 cells/ml) 2.7±0.1* 5.6±0.5 5.6±0.3
Granulocytes
a (%) 4.6±0.6* 28.2±1.9 28.2±1.4
Granulocytes
a (cells/spleen) 50.8±7.8* 598.9±44.1 613.4±29.2
Monocytes
b (%) 2.7±0.2* 5.8±0.2 6.2±0.3
Monocytes
b (cells/spleen) 29.1±2.2* 126.0±8.3 139.6±11.0
Macrophages
c (%) 5.0±0.2 5.0±0.3 4.0±0.2*
Marophages
c (cells/spleen) 54.9±4.2* 110.7±10.9 87.3±5.2
CD3+CD4+ T-cells (%) 6.9±0.4* 3.6±0.2 4.2±0.3
CD3+CD4+ T-cells (cells/spleen) 75.7±5.8 78.7±6.3 90.8±6.2
CD3+CD8+ T-cells (%) 3.2±0.2* 1.7±0.1 1.7±0.1
CD3+CD8+ T-cells (cells/spleen) 35.4±3.2 34.8±2.0 36.9±2.6
Data represent means±s.e.m. of the control (C) group (n¼10), tumour-bearing
control (TB) group (n¼19) and tumour-bearing group after oral administration of
the specific nutritional combination (TB-SNC) (n¼20). *Significantly different
(Po0.025) from the TB group.
aDefined as GR-1
high cells.
bDefined on the base of
forward- and side-scatter profile, F4/80
dull and GR-1
low to dull.
cDefined as F4/80
high cells.
Table 1 Effect of oral administration of fish oil, specific oligosaccharide
mixture or high protein/leucine on physiological cachexia parameters and
immune parameters
Cachexia C TB TB-FO TB-SOM TB-HPrleu
Body weight (g) 24.4±0.3* 22.8±0.4 23.0±0.8 23.8±0.8 21.8±0.6
Tumour weight (g) 0.0±0.0* 2.2±0.1 2.1±0.1 2.2±0.1 1.8±0.1
Carcass weight (g) 24.4±0.3* 20.7±0.4 20.9±0.8 21.5±0.8 20.0±0.6
Immune C TB TB-FO TB-SOM TB-HPrleu
Thymus weight (mg) 35.9±1.2* 18.7±1.0 21.1±2.1* 20.2±2.1 14.5±1.8
Spleen weight (mg) 98.7±2.9* 267.7±8.1 231.1±9.8 284.1±20.5 232.9±15.8
Data from different experiments were combined and represent means±s.e.m. of the
control (C) group (n¼40), tumour-bearing control (TB) group (n¼40) and tumour-
bearing groups after supplementation with fish oil (TB-FO, n¼10), specific
oligosaccharide mixture (TB-SOM, n¼10) or high protein/leucine (TB-HPrleu,
n¼10). *Significantly different (Po0.0125) from the TB group.
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sgranulocytes from 50.8 10
7 cells/spleen in the C group to
598.9 10
7 cells/spleen in the TB group (Table 2). In addition,
monocytes showed a significant increase in the number of cells
per spleen, whereas the total number of CD3þCD4þ and
CD3þCD8þ T cells was not affected. Relatively, the percentages
of CD3þCD4þ and CD3þCD8þ T cells were almost two times
lower in the TB group compared with the C group, probably due to
the high increase of granulocytes. After adding the complete
mixture of nutritional ingredients to the diet of tumour-bearing
mice, no effect was observed on the total number of splenocytes,
neither on the absolute nor on relative number of granulocytes,
monocytes and CD3þCD4þ and CD3þCD8þ T cells.
In cell membranes of the isolated splenocytes, percentages of n-6
and n-3 fatty acids of total phospholipid fatty acids were measured
(data not shown). No effect was observed on the total n-6 fatty
acids content after tumour inoculation, whereas the percentage of
total n-3 was increased significantly in the TB group, probably due
to the significant increase in DHA. After feeding a diet with the
total combination of the nutritional ingredients, total n-6 content
in cell membranes of splenocytes was decreased significantly
compared with the TB group because of a strong reduction in
arachidonic (AA) acid from 19.6% in the TB group to 8.9% in the
TB-SNC group. The percentages of the n-3 fatty acids EPA and
DHA were increased significantly from 0.4 and 2.5%, respectively,
in the TB group to 3.5 and 4.4%, respectively, in the TB-SNC
group, leading to a significantly higher n-3 content.
Plasma cytokine and PGE2 concentrations Pro-inflammatory
cytokines and PGE2 were measured in plasma obtained from blood
at day 20. IL-6, TNF-a as well as PGE2 were increased significantly
from 14.8, 0.3 and 9488pgml
 1, respectively, in the C group to
152.1, 12.3 and 49096pgml
 1, respectively in TB group (Figures
3a–c), whereas IL-1b and IFN-g levels were below the detection
limit of the assay. A strong decline in the production of the pro-
inflammatory cytokine levels, IL-6, TNF-a and PGE2, was observed
at 111.8 (P¼0.038), 7.0 (P¼0.017) and 19601pgml
 1 (Po0.001)
(all one-tailed tested), respectively, after the addition of the
complete mixture of FO, SOM and high protein/leucine to the diet
of tumour-bearing mice, leading to a lower inflammatory state.
Ex vivo ConA-stimulated T-lymphocyte proliferation in
splenocytes In addition to CHS, which was measured prior to
weight loss, ex vivo ConA-stimulated T-lymphocyte proliferation
by splenocytes was measured in cachectic tumour-bearing mice.
Table 3 Effects of oral administration of the complete mixture of fish oil,
specific oligosaccharide mixture and high protein/leucine on ConA-
stimulated cytokine production in whole blood and splenocytes and on
LPS-stimulated cytokine and PGE2 production in whole blood and
splenocytes
ConA-stimulated cytokine
production C TB TB-SNC
Whole blood
IL-2 (% vs C) 100.0±14.0 65.0±7.2 96.3±15.3
IL-4 (% vs C) 100.0±10.5* 11.3±3.1 69.9±23.6*
IL-12 (% vs C) 100.0±8.0 84.7±14.8 75.4±16.1
Splenocytes (FCS
hi)
IL-2 (% vs C) 100.0±11.1* 34.4±2.3 42.3±3.4
IL-4 (% vs C) 100.0±13.3* 45.9±4.9 70.9±11.5*
IFN-g (% vs C) 100.0±10.5* 34.6±8.7 80.0±27.6
LPS-stimulated cytokine
production C TB TB-SNC
Whole blood
IL-1b (% vs C) 100.0±8.1* 17.5±2.7 38.5±15.5
IL-6 (% vs C) 100.0±21.2 72.3±13.3126.9±40.3
TNF-a (% vs C) 100.0±8.3* 18.5±2.4 38.2±15.0
PGE2 (% vs C) 100.0±8.9 137.9±20.4 43.1±3.2*
Splenocytes (FCS
hi)
IL-1b (% vs C) 100.0±4.3 107.5±11.6 97.0±13.6
IL-6 (% vs C) 100.0±8.6* 76.5±12.7107.7±14.5
TNF-a (% vs C) 100.0±4.7 102.7±8.0 102.1±10.4
PGE2 (% vs C) 100.0±2.1* 178.0±12.4196.6±11.4
ConA¼concanavalin A; IL¼interleukin; IFN-g¼Interferon-g; LPS¼lipopolysacchar-
ide; PGE2¼prostaglandin E2; TNF-a¼tumour necrosis factor-a. Data represent
means±s.e.m. of control (C) group (ConA/LPS whole blood n¼10, ConA/LPS
splenocytes n¼7), tumour-bearing control (TB) group (ConA/LPS whole blood
n¼10, ConA/LPS splenocytes n¼13) and tumour-bearing group after oral
administration of the specific nutritional combination (TB-SNC) (ConA/LPS whole
blood n¼10, ConA/LPS splenocytes n¼12). All values were calculated as
percentage of the control group, which is set at 100%. *Significant differently
(Po0.025) from tumour bearing control group (TB).
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Figure 2 Effects of oral administration of the complete mixture of fish
oil, specific oligosaccharide mixture and high protein/leucine on contact
hypersensitivity (A) and ConA-stimulated T-lymphocyte proliferation by
splenocytes (B). Data represent means±s.e.m. of the control (C) group
(n¼10), tumour-bearing control (TB) group (n¼19) and tumour-bearing
group after oral administration of the specific nutritional combination
(TB-SNC) (n¼20). For ConA-stimulated T-lymphocyte proliferation, all
values were calculated as the percentage of the control group, which is set
at 100%. *Significantly different (Po0.025) from the TB group.
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Figure 3 Effects of oral administration of the complete mixture of fish
oil, specific oligosaccharide mixture and high protein/leucine on plasma
cytokine IL-6 (A), TNF-a (B), IL-4 (C) and PGE2 (D) concentrations. Data
represent means (pgml
 1)±s.e.m. of the control (C) group (n¼10),
tumour-bearing control (TB) group (n¼19) and tumour-bearing group
after oral administration of the specific nutritional combination (TB-SNC)
(n¼20). *Significantly different (Po0.025) from the TB group.
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values were calculated as percentage of the control group, which is
set at 100%) to 47.0% in the TB group (Figure 2b). After adding the
complete mixture of nutritional ingredients to the tumour-bearing
mice, a strong trend to an improved immune response was
observed, although this effect was not significant (P¼0.031).
Ex vivo ConA and LPS-stimulated cytokine production in whole
blood and splenocytes In ConA-stimulated whole blood and
splenocytes, both Th1 and Th2 cytokines were measured, whereas
in LPS-stimulated whole blood and splenocytes, pro-inflammatory
cytokines and PGE2 were measured. All values were calculated as
the percentage of the control group, which is set at 100%. In ConA-
stimulated whole blood, IL-4 (Th2 cytokine) production was
reduced significantly from 100% in the C group to 11.3% in the TB
group (Table 3). Moreover, in ConA-stimulated splenocytes, IL-4
(Th2) as well as IL-2 and IFN-g (Th1) were decreased significantly
in the TB group. After administration of the complete mixture
of FO, SOM and high protein/leucine to the tumour-bearing mice,
IL-4 production in both ConA-stimulated whole blood and
splenocytes showed a significant increase (Po0.025).
In LPS-stimulated whole blood, both IL-1b and TNF-a were
decreased significantly from 100% in the C group to 17.5 and
18.5%, respectively, in the TB group (Table 3). In addition, a trend
to decreased IL-6 levels was observed, whereas PGE2 showed a
trend to enhanced levels in the TB group. In LPS-stimulated
splenocytes, IL-6 was reduced significantly in the TB group
compared with the C group. By contrast, PGE2 production showed
a significant increase from 100% in the C group to 178% in the TB
group. After feeding a diet with the complete mixture of nutritional
ingredients, PGE2 production in LPS-stimulated whole blood was
decreased significantly from 137.9% in the TB group to 43.1% in
the TB-SNC group, whereas PGE2 production in LPS-stimulated
splenocytes was not affected.
DISCUSSION
This study showed a significant improved Th1 immune response
after feeding a diet containing the complete mixture of nutritional
ingredients FO, SOM and high protein/leucine in tumour-bearing
animals in a pre-cachectic state. In addition, in mice already
suffering from cachexia, the complete mixture of ingredients
affected several physiological and immune parameters, represent-
ing a lower inflammatory state, better immune responses and less
wasting of protein and lipid stores, leading to less severe cachexia.
The cachectic features of the C26 mouse model have been
described earlier by other authors, who attributed a pivotal role for
the pro-inflammatory cytokine IL-6 in the induction of cachexia
(Tanaka et al, 1990; Strassmann et al, 1992a; Tanaka et al, 1993;
Soda et al, 1994). In the current study, parameters of immune
competence were measured in parallel to cachexia- and inflamma-
tion-related parameters, to study cachexia-related immune dys-
function in this model as well. To this end, in vivo Th1-related
immune function was quantified using oxazolone-induced CHS
responses. In addition, several ex vivo parameters were measured
in whole blood and isolated splenocytes cultures.
In both experiments A and B, BW and CW were reduced
significantly in the TB group, which is in accordance with a
significant reduction in the weight of epididymus fat and skeletal
muscles and argues for a cachectic status of the mice. In
experiment B, the pro-inflammatory cytokines IL-6 and TNF-a
were measured. These cytokines have been described as pro-
cachectic cytokines involved in different metabolic changes
associated with wasting during cancer cachexia (Toomey et al,
1995; Argiles et al, 2003; Argiles, 2005). In literature, TNF-a levels
measured in the C26 model were below the detection limit
(Strassmann et al, 1992a; Soda et al, 1994). In this study, however,
TNF-a levels can be measured, in spite of the low levels, and
differences between groups were determined. Both IL-6 and TNF-a
levels were increased significantly in the TB group, which
confirmed the role of TNF-a besides IL-6, in the pathogenesis of
cancer cachexia in the C26 model. By contrast, levels of IL-4, in
literature stated as an anti-cachectic cytokine (Argiles et al, 2003),
showed a significant decrease in the TB group, which is in
agreement with the cachectic state of the animals.
Contact hypersensitivity responses were measured in a pre-
cachectic state and were reduced significantly in the TB group,
indicating an impaired Th1 immune response in tumour-bearing
mice before the onset of weight loss. In earlier experiments, CHS
was also determined in mice already suffering from cachexia,
showing an even stronger reduction (unpublished data). It should
be realised that this reduction was severe because of the dramatic
health status of the mice at this time point, therefore the effect of
the nutritional ingredients was only determined in a pre-cachectic
state. Nevertheless, in cachectic mice, ex vivo parameters were
measured to assess immune competence.
To evaluate the potential benefits of specific nutritional
interventions on cachexia features and immune function,
FO, SOM and high protein/leucine were added to the diet of
tumour-bearing mice. No effect of the individual ingredients
was shown on BW, CW, epididymus fat weight and weight of
skeletal muscles, indicating no advances in the poor cachectic state
of the mice. This was confirmed by the absence of potential effects
on immune function, measured by CHS in a pre-cachectic state.
When FO in combination with high protein/leucine was added
to the diet, BW, CW and weights of epididymus fat and the skeletal
muscle mTA were improved significantly (unpublished data).
Moreover, CHS responses appear to show a small increase,
but this was far from significant (P¼0.716) compared with
animals in the TB group (data not shown). However, after the
addition of the complete mixture of FO, SOM and high protein/
leucine to the diet of tumour-bearing animals, a significant
increase in ear swelling was observed compared with those in
the TB group, indicating an improved Th1 immune response
leading to a better resistance against infections. In addition, in
mice already suffering from cachexia, physiological parameters as
BW, CW and weights of epididymus fat and skeletal muscles
showed a significant increase after adding the complete mixture of
nutritional ingredients to the diet compared with the reduction
observed in TB mice (Table 2). Consequently, the cachectic state of
the mice was reduced significantly, and muscle function and daily
activity, important contributors to the quality of life, were
improved significantly (unpublished data). Taken together, the
results indicate that the combination of the nutritional ingredients
FO, SOM and high protein/leucine is able to induce a synergistic
effect, leading to less severe cachexia and improved immune
responses.
Thymus weight was decreased after tumour inoculation and
showed a significant recovery after adding the complete mixture of
FO, SOM and high protein/leucine to the diet. The thymus is one of
the central primary lymphoid organs and plays an important role in
cellular immunity by generating circulating T lymphocytes (Delves
and Roitt, 2000). Therefore, the recovery of thymus weight is of
major importance for an efficient working and balanced immune
system. In contrast to thymus weight, spleen weight was elevated in
the TB group. This is mainly caused by a strong increase in both
percentage and total number of granulocytes among the total
splenocytes population. In literature this is known as a leukemoid
reaction, which is earlier described in tumour-bearing mice and in
different types of human cancers (Nimieri et al, 2003; DuPre and
Hunter, 2007). When the complete mixture of FO, SOM and high
protein/leucine was added to the diet of tumour-bearing animals,
the leukemoid reaction was not reduced. Therefore, the beneficial
effect of nutritional intervention on immune function is argued to
be due to other effects on the immune system.
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were performed to determine immune function in cachectic mice.
In ConA-stimulated splenocytes cultures from TB mice, a
significant reduction in T-lymphocyte proliferation and both Th1
and Th2 cytokine production was observed, probably caused by a
relative decrease in the number of T lymphocytes and by a lower
activity. Moreover, also in ConA-stimulated whole blood, Th1 and
Th2 cytokines were affected, which is probably the consequence of
a general reduction in T-cell activity. These results are consistent
with the immune suppression that was observed in vivo by the
measurement of CHS. In LPS-stimulated whole blood, a significant
reduction was observed on IL-1b and TNF-a production in the TB
group, representing a reduced capacity of immune cells to react to
an infection ex vivo. IL-6 showed a trend to a decrease and PGE2
even tended to an increase, possibly due to the high serum levels in
plasma that were also present in whole blood.
After adding the complete mixture of FO, SOM and high
protein/leucine to the diet of TB mice, ConA-stimulated T-cell
responses were positively affected both in splenocytes and in whole
blood. In addition, LPS-stimulated IL-1b, TNF-a and IL-6
production by whole blood showed a trend to an increase
compared to TB mice, indicating an enhanced capacity of immune
cells to mount acute infection-like responses ex vivo. By contrast,
LPS-stimulated PGE2 production was decreased significantly in the
TB-SNC group, which might be explained by the absence of high
PGE2 levels in plasma or by the inhibitory effect of the complete
mixture in the ex vivo situation.
As mentioned before, plasma levels of the pro-inflammatory
cytokines IL-6 and TNF-a were increased significantly in cachectic
TB mice, leading to a chronic inflammatory state. Together with
PGE2, another inflammatory mediator that is enhanced signifi-
cantly in TB mice, these cytokines play a central role in the
induction of the immune suppression observed in these tumour-
bearing mice (Young, 1994). After feeding a diet with the complete
mixture of FO, SOM and high protein/leucine, IL-6 levels in plasma
showed a tendency to a decrease and TNF-a levels were decreased
significantly compared with those in the TB group. Inhibition of
IL-6 production in this cachexia model is established to prevent
the development of cachexia as shown after treatment with a
murine antibody to IL-6 (Strassmann et al, 1992a), whereas TNF-a
is thought to play an important role in wasting of fat and to induce
IL-6 secretion by many cell types (Strassmann et al, 1992b).
Nevertheless, IL-6 is not only produced by TNF-a signalling, it is
thought that in animals carrying C26 tumours, the majority of IL-6
is produced by the tumour cells in response to macrophages
residing in these tumours, leading to the severe inflammatory
state inducing different catabolic processes involving cachexia
(Strassmann et al, 1992b). Accordingly, the observed reduction in
IL-6 and TNF-a levels in the TB-SNC group might partly account
for the reduced inflammatory state and the improved functional
aspects of the catabolism associated immune suppression. Also
PGE2 might be involved in this process. PGE2 can be secreted by
many cell types, including monocytes, macrophages and tumour
cells, and suppresses multiple immune functions as T-lymphocyte
proliferation and macrophage activation (Ben-Baruch, 2006). After
adding the complete mixture of nutritional ingredients, PGE2 levels
in plasma of tumour-bearing animals were reduced significantly
compared with those in the TB group. This might be the result
of the incorporation of the n-3 PUFA EPA (present in FO) in cell
membrane phospholipids that leads, by a reduction in the
percentage arachidonic acid, to a decreased production of PGE2
by the cyclooxygenase enzyme (Ross and Fearon, 2002; Trebble
et al, 2003). In literature, FO has been established to possess anti-
cachectic, anti-inflammatory and immune modulating properties,
both in vivo and ex vivo, but dose and ratio of the n-3 PUFA EPA
and DHA are described as important factors that determine these
properties (Argiles, 2005; van Bokhorst-de van der Schueren, 2005;
Pizato et al, 2006; Sijben and Calder, 2007). The FO dose of 22.1g
(providing 6.9g EPA and 3.1g DHA) per kg food described in the
experiments with the individual nutritional ingredients (experi-
ments A) reported nevertheless no effect on both physiological and
immunological parameters, whereas the double dose tested in this
model showed significant improved cachectic features and a trend
to enhanced immune function measured by CHS (data not shown).
In addition, no effect of adding the SOM was observed on cachexia
and immune parameters (experiments A) in tumour-bearing
animals, whereas a mixture of 2% (w/w) specific oligosaccharides
in a 9:1 ratio induced Th1 immunity in an influenza vaccination
model in healthy C57BL/6 mice (Vos et al, 2006). However, when
the FO dose of 22.1g (providing 6.9g EPA and 3.1g DHA) is
combined with the SOM and high protein/leucine, less severe
cachexia and significant improved immune responses were shown.
To this end, it seems that besides inhibition of the chronic
inflammatory state present in the cachectic mice, it is also required
to support the nutritional state of the mice with the combination of
ingredients to obtain positive effects on immune function.
In conclusion, this study showed the beneficial immune
modulatory effects of the SNC, leading to a multitarget approach.
No effect was observed after feeding a diet containing the individual
nutritional ingredients FO, SOM or high protein/leucine on CHS in
tumour-bearing animals in a pre-cachectic state. In contrast, the
complete mixture of nutritional ingredients reported a significant
improved Th1 immune response in tumour-bearing mice prior to
weight loss. In mice already suffering from cachexia, the complete
mixture of ingredients affected several physiological and immune
parameters, representing a lower inflammatory state, better
immune responses and less wasting of protein and lipid stores,
leading to less severe cachexia. Accordingly, the combination of the
nutritional ingredients FO, SOM and high protein/leucine is able to
induce a synergistic effect, leading to an improved health status of
the mice related to immune competence, weight gain and multiple
inflammatory indices. From this, it can be concluded that the SNC
has potential as immune-supporting nutritional intervention. As
shown in this study, immune function in tumour-bearing mice is
already affected before the onset of weight loss. Therefore, it is very
important to provide nutritional support with immune-modulating
properties as early as possible in order to stop or reverse the
nutritional decline, slowing down the progression of cachexia and
counteract dysfunction of the immune system to reduce the risk of
(infectious) complications. Currently, clinical studies with cancer
patients are being performed to study whether mentioned effects
can be extrapolated to the human setting.
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